HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Extended-Release Acetaminophen Launch Delayed By QC Issues

This article was originally published in The Tan Sheet

Executive Summary

Perrigo has postponed its plans to market private label extended-release acetaminophen until it can resolve quality control issues outlined in a recent FDA warning letter.

You may also be interested in...

GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth

The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth

Perrigo Liquid Pain Reliever Recall Prompted By Excess Acetaminophen

Perrigo is recalling nearly 8,000 bottles of cherry-flavored pain reliever suspension liquid manufactured at its Allegan, Mich. facility.

Perrigo Multiple Acquisitions Expected In Next 12 Months - CEO Gibbons

Perrigo is eyeing possible near-term acquisition candidates in three main areas - global operations, nutritionals and new delivery vehicles - as the private labeler comes closer to putting its recent operational woes behind it.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts